ArticleMolecular diversity2023
Design, synthesis and mechanism study of novel natural-derived isoquinoline derivatives as antifungal agents.
Article in Molecular diversity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 19 citations in OpenAlex.
- Recent Advances in Synthetic Isoquinoline-Based Derivatives in Drug Design.Molecules (Basel, Switzerland) · 2025Review
- Design, synthesis, bioactivity and action mechanism of N-substituted N'-phenylpicolinohydrazides against phytopathogenic fungi.Molecular diversity · 2025Article
- Diversely functionalized isoquinolines and their core-embedded heterocyclic frameworks: a privileged scaffold for medicinal chemistry.RSC medicinal chemistry · 2023Review
- Various Biomimetics, Including Peptides as Antifungals.Biomimetics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
In screening for natural fungicidal leads, two series of novel 3-aryl-isoquinoline derivatives 8 and 9 were designed and synthesized based on sanguinarine, chelerythrine and berberine. Their structures were confirmed by 1D, 2D NMR and HRMS. Most of the title compounds showed medium to excellent antifungal activity in vitro at 50 mg/L, which were much more active than the lead of sanguinarine. Especially, 9f possessed the best effective against Alternaria solani (80.4%), Alternaria alternata (88.2%) and Physalospora piricola (93.8%). Furthermore, the EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.